CAJ | 학술논문

目的评价细胞因子诱导的杀伤细胞(CIK)细胞治疗转移性肾癌(MRCC)的临床疗效.方法 2010年5月至2011年11月入住河南省肿瘤医院(郑州大学附属肿瘤医院)生物治疗科经病理确诊的21例MRCC患者,所有患者均接受至少4周期CIK细胞治疗.治疗后定期复查,评价疗效.主要观察指标为疾病控制率(DCR)和至疾病进展时间(TTP),次要观察指标为不良反应发生率和影响患者TTP的因素,主要观察指标TTP采用Kaplan-Meier方法分析,影响TTP的因素采用Log-Rank方法分析.结果 21例患者中部分缓解(PR)1例,疾病稳定(SD)16例,疾病进展(PD)4例,疾病控制率(DCR)为80.95％(17/21),中位TTP为11.68个月；所有患者主要不良反应是发热,发生率为19.05％ (4/21)；亚组分析表明发生肺转移的、CIK细胞治疗周期多的患者具有更长的TTP,差异具有统计学意义P＜0.05.结论 CIK细胞是转移性肾癌患者安全、有效的治疗方法,疗效和靶向治疗的疗效相当.但患者不良反应小,耐受性良好,肺转移患者及CIK细胞治疗周期多的患者TP更长.
목적 평개세포인자유도적살상세포(CIK)세포치료전이성신암(MRCC)적림상료효.방법 2010년5월지2011년11월입주하남성종류의원(정주대학부속종류의원)생물치료과경병리학진적21례MRCC환자,소유환자균접수지소4주기CIK세포치료.치료후정기복사,평개료효.주요관찰지표위질병공제솔(DCR)화지질병진전시간(TTP),차요관찰지표위불량반응발생솔화영향환자TTP적인소,주요관찰지표TTP채용Kaplan-Meier방법분석,영향TTP적인소채용Log-Rank방법분석.결과 21례환자중부분완해(PR)1례,질병은정(SD)16례,질병진전(PD)4례,질병공제솔(DCR)위80.95％(17/21),중위TTP위11.68개월；소유환자주요불량반응시발열,발생솔위19.05％ (4/21)；아조분석표명발생폐전이적、CIK세포치료주기다적환자구유경장적TTP,차이구유통계학의의P＜0.05.결론 CIK세포시전이성신암환자안전、유효적치료방법,료효화파향치료적료효상당.단환자불량반응소,내수성량호,폐전이환자급CIK세포치료주기다적환자TP경장.
Objective To investigate the clinical efficacy of cytokine induced killer cells(CIK) for the treatment of metastatic renal cell carcinoma (MRCC).Methods We analyzed 21 cases of MRCC,who received more than 4 cycles CIK cells therapies.All the patients were from the department of biotherapy of He Nan cancer hospital.Our primary endpoints were disease control rate (DCR) and time to progression (TTP),secondary endpoints were incidence of adverse reactions and the influencing factors for TTP,all data were through statistical analysis.Results Of the 21 patients,1 had partial remission(PR),16 had stable disease (SD),4 had with progressed disease (PD),DCR(PR + SD) accounted for 80.95％ (17/21).The overall median TTP was 11.68 months.Patients with lung metastasis or/and more than 6 might have longer TTP than other patients(P ＜ 0.05).Conclusion CIK cells therapy is safe and efficacy for MRCC,which have the equal efficacy of targeted therapy.However,adverse events are lower than targeted therapy and patients are well tolerated,patients with lung metastasis or increasing the cycles of CIK cell therapy may prolong TTP of patients with MRCC.